Riccardo De Giorgi on semaglutide and neurological and psychiatric outcomes

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/c4/45/1b/c4451be5-4daa-1dda-abc1-9ad2ada74fc0/mza_9041289620623617024.jpg/600x600bb.jpg

eClinicalMedicine in conversation with

The Lancet Group

42 episodes

2 weeks ago

Giulia Zamagni joins Claudia Schaefer to discuss her recent Series of 4 papers from the Italian Global Burden of Disease collaborators providing the disease burden estimates and temporal trends for leukemia, multiple myeloma, non-Hodgkin lymphoma and Hodgkin lymphoma in Italy. Click here to read the full text in this series: paper 1; paper 2; paper 3; paper 4 Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup...

All content for eClinicalMedicine in conversation with is the property of The Lancet Group and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Riccardo De Giorgi on semaglutide and neurological and psychiatric outcomes

eClinicalMedicine in conversation with

28 minutes

1 year ago

Riccardo De Giorgi on semaglutide and neurological and psychiatric outcomes

Riccardo De Giorgi joins Elena Bellafante, Deputy Editor for eClinicalMedicine, to discuss the evidence that semaglutide may be associated with a reduced risk of a number of neurological and psychiatric outcomes, including cognitive deficits and dementia, as well as nicotine misuse.Read the full article:https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00305-5/fulltext?dgcid=buzzsprout_tlv_podcast_generic_eclinmContinue this conversation on social!Follow us today at...https:/...